Pain News and Research

Latest Pain News and Research

Lilly receives fourth FDA approval for CYRAMZA (ramucirumab)

Eli Lilly and Company has received its fourth U.S. Food and Drug Administration approval for CYRAMZA (ramucirumab). CYRAMZA (ramucirumab injection 10 mg/mL solution) is now also indicated in combination with FOLFIRI (irinotecan, folinic acid, and 5-fluorouracil) chemotherapy for the treatment of patients with metastatic colorectal cancer (mCRC) with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine.

25 Apr 2015

Xstrahl introduces Phtotoelectric therapy to the European market at ESTRO 2015

Utilising trusted and clinically proven low energy photons, in a dedicated treatment system. Photoelectric Therapy provides a pain free, non-surgical alternative for the treatment of non-melanoma skin cancer, especially those found in sensitive areas of the head and neck...

24 Apr 2015

Study points to TMPRSS2 gene as culprit for aggressive forms of androgen-fuelled cancers

A new study led by University of Toronto researcher Dr. David Lam has discovered the trigger behind the most severe forms of cancer pain. Released in top journal Pain this month, the study points to TMPRSS2 as the culprit: a gene that is also responsible for some of the most aggressive forms of androgen-fuelled cancers.

24 Apr 2015

FDA announces voluntary recall of Zimmer knee product

MT Services LLC, a Lawsuit Settlement News Reporting Company which operates lawsuitsettlementnews.com, announced today that the FDA announced a Class II recall for Zimmer's Persona Trabecular Metal Tibial Plate knee implant. The recall affects all lots and sizes of the knee implant, affecting all 11,658 devices that were recalled, according to the FDA's website.

23 Apr 2015

New brain mapping model could improve success rate of transcranial magnetic stimulation

Brain researchers from the Perelman School of Medicine at the University of Pennsylvania have developed a new brain mapping model which could improve the success rate of transcranial magnetic stimulation (TMS) in treating conditions including depression, neuropathic pain, and stroke.

23 Apr 2015

UC San Diego, Scripps partner to improve patient care, physician training and research in hospice medicine

UC San Diego Health System and Scripps Health are partnering to provide improved continuity of patient care, fellowship training and research in hospice and palliative medicine. Under a new five-year agreement, Scripps will work with UC San Diego to provide outpatient and inpatient hospice care for UC San Diego patients, allowing UC San Diego physicians to better coordinate post-acute care for patients with chronic illness.

23 Apr 2015

VisualDx tool aids physicians in diagnosing dermatologic conditions

In the first major study to examine the use of a computer-assisted, photo-driven differential diagnosis generator for skin conditions, researchers at the Perelman School of Medicine at the University of Pennsylvania found physicians routinely used the tool, without an increase in calling for inpatient dermatology consultations.

23 Apr 2015

Ebola survivors face long-term adverse health effects: Study

Ebola survivors experienced negative health effects that persisted more than two years after the 2007-2008 Bundibugyo ebolavirus (BDBV) outbreak in Uganda that claimed 39 lives. These findings are detailed in a paper published online today in Lancet ID.

23 Apr 2015

Advances in thoracic surgery: an interview with Dan Wildman, VP Global Franchise Strategy & Innovation- Ethicon

Without a doubt, one of the most significant developments in thoracic surgery was the advent of video-assisted thoracoscopic surgery or VATS in the 1990s...

22 Apr 2015

Nuvo Research provides details of new WF10 Phase 2 clinical trial for treatment of allergic rhinitis

Nuvo Research Inc., a specialty pharmaceutical company with a diverse portfolio of topical and immunology products, today announced additional details of its new Phase 2 clinical trial (the 2015 WF10 Trial) to assess WF10 for the treatment of allergic rhinitis.

22 Apr 2015

Data from pacritinib Phase 3 PERSIST-1 trial in patients with myelofibrosis to be highlighted at ASCO

CTI BioPharma Corp. and Baxter International Inc. today announced that data from the randomized Phase 3 PERSIST-1 trial evaluating the investigational agent pacritinib in patients with myelofibrosis will be highlighted in a late-breaking oral presentation at the upcoming American Society of Clinical Oncology 2015 Meeting (May 29-June 2, 2015 in Chicago, Ill).

From Baxter International Inc. 22 Apr 2015

Discovery unveils novel drug targets to halt peripheral neuropathies, neurodegenerative disorders

New research highlights how nerves - whether harmed by disease or traumatic injury - start to die, a discovery that unveils novel targets for developing drugs to slow or halt peripheral neuropathies and devastating neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis (ALS).

22 Apr 2015

French clinicians diagnose first case of rabies since 2003

A team of French clinicians has diagnosed the first case of rabies in that country since 2003. Only 20 cases of human rabies had been diagnosed in France between 1970 and 2003. Moreover, the patient was unaware of having been bitten.

22 Apr 2015

New research examines what happens when MS patients discontinue their medication

New research led by NYU Langone Medical Center examines what happens when a patient with multiple sclerosis (MS) who is clinically stable stops taking their medication.

22 Apr 2015

Upsher-Smith presents favorable data from PREVAIL OLE study of Qudexy XR capsules

Upsher-Smith Laboratories, Inc. presented data from a 52-week, open-label extension study (PREVAIL OLE) showing that Qudexy XR (topiramate) extended-release capsules offered a long-term adjunctive treatment option with a favorable tolerability profile for a high proportion of patients with refractory partial-onset seizures (POS).

21 Apr 2015

Montefiore and Einstein researchers to present new findings on neurological disorders at AAN 2015

Researchers from Montefiore Health System and Albert Einstein College of Medicine will present new findings on how to effectively treat migraine, and forecast the onset of pain in a number of neurological conditions including dementia in older adults.

21 Apr 2015

Incidence of esophageal cancer linked to GERD rises six-fold in recent decades

Esophageal cancer is one of the fastest-growing and deadliest cancers in the U.S. According to the American Cancer Society, an estimated 17,000 new cases of esophageal cancer will be diagnosed in 2015. Incidence of adenocarcinoma, a type of esophageal cancer linked to GERD (gastroesophageal reflux disease) has risen six-fold in recent decades.

21 Apr 2015

Ibrutinib (IMBRUVICA) may be effective for pancreatic ductal adenocarcinoma

Ibrutinib (IMBRUVICA) data presented yesterday by Pharmacyclics, Inc. at the American Association for Cancer Research Annual Meeting suggest that ibrutinib may be an effective therapeutic option for pancreatic ductal adenocarcinoma (PDAC), as shown in both a transgenic mouse model and an in-vivo model of patient-derived xenograft (PDX) mice (grafts of tissue taken from a pancreatic cancer patient and grafted into a mouse).

20 Apr 2015

Bionomics begins BNC210 Phase II clinical trial for treatment of anxiety, depression

Bionomics Limited, a biopharmaceutical company focused on the discovery and development of innovative therapeutics for the treatment of cancer and diseases of the central nervous system, today announced the initiation of a Phase II clinical study of BNC210, the Company's drug candidate in development for the treatment of anxiety and depression.

20 Apr 2015

Plaque can be used to predict, identify and treat diseases, say researchers

Scraped from the gums, teeth and tongue in the form of plaque, the researchers behind Canada's first plaque bank are betting that the bacterial content of plaque will open up a new frontier of medicine.

17 Apr 2015

Pain News and Research

Latest Pain News and Research

Lilly receives fourth FDA approval for CYRAMZA (ramucirumab)

Xstrahl introduces Phtotoelectric therapy to the European market at ESTRO 2015

Study points to TMPRSS2 gene as culprit for aggressive forms of androgen-fuelled cancers

FDA announces voluntary recall of Zimmer knee product

New brain mapping model could improve success rate of transcranial magnetic stimulation

UC San Diego, Scripps partner to improve patient care, physician training and research in hospice medicine

VisualDx tool aids physicians in diagnosing dermatologic conditions

Ebola survivors face long-term adverse health effects: Study

Advances in thoracic surgery: an interview with Dan Wildman, VP Global Franchise Strategy & Innovation- Ethicon

Nuvo Research provides details of new WF10 Phase 2 clinical trial for treatment of allergic rhinitis

Data from pacritinib Phase 3 PERSIST-1 trial in patients with myelofibrosis to be highlighted at ASCO

Discovery unveils novel drug targets to halt peripheral neuropathies, neurodegenerative disorders

French clinicians diagnose first case of rabies since 2003

New research examines what happens when MS patients discontinue their medication

Upsher-Smith presents favorable data from PREVAIL OLE study of Qudexy XR capsules

Montefiore and Einstein researchers to present new findings on neurological disorders at AAN 2015

Incidence of esophageal cancer linked to GERD rises six-fold in recent decades

Ibrutinib (IMBRUVICA) may be effective for pancreatic ductal adenocarcinoma

Bionomics begins BNC210 Phase II clinical trial for treatment of anxiety, depression

Plaque can be used to predict, identify and treat diseases, say researchers

How cohesin mechanics and nanotracker tech are redefining DNA research

Todd Bauman and Chris Povich

Scaling organ‑chip technology for human‑relevant drug discovery

Pain News and Research

Latest Pain News and Research

How cohesin mechanics and nanotracker tech are redefining DNA research

Todd Bauman and Chris Povich

Scaling organ‑chip technology for human‑relevant drug discovery

Newsletters you may be interested in